You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The new service, slated for launch in the second half of 2021, will allow Myriad to expand its cancer tumor profiling services.
The liquid biopsy method analyzes fragment ends within recurrently protected regions in cell-free DNA from a patient's urine sample.
SUGAR-seq, a single-cell method developed by researchers in Australia, is a first step towards analyzing differences in glycosylation in various cell types.
The company recently announced a deal with personalized ctDNA testing firm Natera and will now follow that with the launch of its own MRD product this year.
The products combine next-generation sequencing and analysis with the company's NGSengine software to provide high-resolution HLA genotyping information.
The genomics company reported revenues of $20.2 million for the quarter, driven by growth in its pharmaceutical services business and other non-VA customers.
The firm posted total software-related revenues of $18.6 million, up 1 percent from $18.4 million in Q4 2019.
Adaptive Cofounder and Chief Scientific Officer Harlan Robins compared the launch of the test to the unveiling of the Tesla Roadster electric sports car.
With a long-read sequencing and de novo genome assembly strategy, investigators found structural variants and hotspots that have been missed in the past.
The firm expects to release an expanded liquid biopsy panel this year to help pharmaceutical partners perform blood-based biomarker discovery work.
The firm will use the funds primarily to expand a beta program supporting a full commercial launch of its first platform, the Miro Canvas sample prep system.
The immune cell sequencing company beat Wall Street estimates on the top line, but missed on the bottom line for both Q4 and full-year 2020.
Researchers identified new cell cycle proteins and their expression through single-cell transcriptome sequencing, proteomic, and other approaches.
The partners will develop a test to identify women most likely to benefit from VGX-3100, Inovio's immunotherapy to treat HPV-associated advanced cervical dysplasia.
The firm reported revenues of $126.0 million for the three-month period ended Dec. 31, 2020, up from $106.9 million in the same period last year.
The platform, based on the firm's Hi-C technology, is designed to assembly viral genomes from metagenomic samples and associate them with their microbial hosts.
Under the Ge-Med project, University Hospital Tübingen will offer diagnostic whole-genome sequencing for all genetic indications and will include PRS in its reporting.
The expanded partnership includes a commercial agreement for the ClonoSeq and ImmunoSeq assays, as well as a lab service agreement for the T-Detect COVID test.
The Chinese company will use the funds to accelerate the registration and commercialization of its NGS-based products for cancer screening and early detection.
The researchers found new molecular pathways of resistance, including hypoxia tolerance, protein folding, and mitochondria respiration.
A UK study on mixing SARS-CoV-2 vaccines is expanding to include vaccines developed by additional companies, according to the Guardian.
According to Science, the US National Academy of Sciences is poised to eject two members accused of sexual harassment.
In Nucleic Acids Research this week: machine learning approach to detect DNA-bound proteins, CRISPR-based method for activating specific gene targets, and more.
The FDA and CDC call for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine while reports of rare blood clots are looked into, reports the Wall Street Journal.